2020
Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study
Taylor JH, Appel S, Eli M, Alexander-Bloch A, Maayan L, Gur RE, Bloch MH. Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study. Journal Of Child And Adolescent Psychopharmacology 2020, 31: 46-52. PMID: 32633541, PMCID: PMC7891207, DOI: 10.1089/cap.2020.0030.Peer-Reviewed Original ResearchConceptsClinical Global Impression-ImprovementClinical responseEarly Onset Schizophrenia Spectrum Disorders StudySymptom improvementWeek 8Early-onset schizophrenia spectrum disordersClinical response timeWeeks of treatmentProportional hazards regressionDisorders StudyTime courseSchizophrenia spectrum disordersClinical nonresponseMedication differencesClinical respondersTreatment initiationClinical nonrespondersMedian timeHazards regressionAntipsychotic treatmentEarly improvementSchizoaffective disorderClinical judgmentMore weeksYouth ages 8
2015
Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial.
Jakubovski E, Carlson JP, Bloch MH. Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial. The Journal Of Clinical Psychiatry 2015, 76: 1535-45. PMID: 26581028, DOI: 10.4088/jcp.14m09320.Peer-Reviewed Original ResearchConceptsIntervention Effectiveness (CATIE) trialTreatment outcomesClinical Antipsychotic TrialsBaseline characteristicsTreatment continuationCATIE trialAntipsychotic pharmacotherapyPrognostic subgroupsEffectiveness trialAntipsychotic TrialsLogistic regressionROC analysisMonths of treatmentImportant treatment outcomesDSM-IV diagnosisPatients' social isolationNegative Syndrome ScaleSocial isolationPoor outcomeZiprasidone treatmentAntipsychotic treatmentComorbid depressionSide effectsPsychosocial factorsSyndrome ScaleObstetric and Neonatal Outcomes After Antipsychotic Medication Exposure in Pregnancy
Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and Neonatal Outcomes After Antipsychotic Medication Exposure in Pregnancy. Obstetrics And Gynecology 2015, 125: 1224-1235. PMID: 25932852, PMCID: PMC4418034, DOI: 10.1097/aog.0000000000000759.Peer-Reviewed Original ResearchConceptsAdverse birth outcomesGestational-age birthsAntipsychotic exposureNeonatal outcomesCohort studyBirth outcomesAntipsychotic medicationMajor malformationsBirth weightOdds ratioAntipsychotic medication exposureNeonatal birth weightPooled odds ratioPotential risk factorsUnexposed pregnanciesMedication exposurePreterm deliveryGestational ageAntipsychotic treatmentElective terminationPossible confoundersReproductive ageRisk factorsSpontaneous abortionSTUDY SELECTION